NASDAQ:XOMA - Nasdaq - US98419J2069 - Common Stock - Currency: USD
XOMA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMA while its profitability can be described as average. XOMA is valued quite expensively, but it does show have an excellent growth rating.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -8.74% | ||
ROE | -21.96% | ||
ROIC | 0.19% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 1.03% | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.18 | ||
Debt/FCF | N/A | ||
Altman-Z | -6.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.54 | ||
Quick Ratio | 5.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 556.72 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 249.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
23.85
-0.75 (-3.05%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 556.72 | ||
P/S | 6.43 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.37 | ||
P/tB | 4.82 | ||
EV/EBITDA | 249.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -8.74% | ||
ROE | -21.96% | ||
ROCE | 0.24% | ||
ROIC | 0.19% | ||
ROICexc | 0.36% | ||
ROICexgc | 0.49% | ||
OM | 1.03% | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.18 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 82.05 | ||
Cap/Depr | 2651.64% | ||
Cap/Sales | 45.45% | ||
Interest Coverage | 0.04 | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.54 | ||
Quick Ratio | 5.54 | ||
Altman-Z | -6.05 |